Arbutus Biopharma Corporation - Product Pipeline Review

Global Markets Direct’s, ‘Arbutus Biopharma Corporation - Product Pipeline Review - 2016’, provides an overview of the Arbutus Biopharma Corporation’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Arbutus Biopharma Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Arbutus Biopharma Corporation

The report provides overview of Arbutus Biopharma Corporation including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Arbutus Biopharma Corporation’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Arbutus Biopharma Corporation’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Arbutus Biopharma Corporation’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Arbutus Biopharma Corporation

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Arbutus Biopharma Corporation’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Arbutus Biopharma Corporation Snapshot 6

Arbutus Biopharma Corporation Overview 6 ...

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Arbutus Biopharma Corporation Snapshot 6

Arbutus Biopharma Corporation Overview 6

Key Information 6

Key Facts 6

Arbutus Biopharma Corporation - Research and Development Overview 7

Key Therapeutic Areas 7

Arbutus Biopharma Corporation - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Pipeline Products - Partnered Products 11

Partnered Products/Combination Treatment Modalities 12

Pipeline Products - Out-Licensed Products 13

Out-Licensed Products/Combination Treatment Modalities 14

Arbutus Biopharma Corporation - Pipeline Products Glance 15

Arbutus Biopharma Corporation - Clinical Stage Pipeline Products 15

Phase II Products/Combination Treatment Modalities 15

Arbutus Biopharma Corporation - Early Stage Pipeline Products 16

Preclinical Products/Combination Treatment Modalities 16

Discovery Products/Combination Treatment Modalities 17

Arbutus Biopharma Corporation - Drug Profiles 18

ARB-1467 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

AB-423 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

ARB-1740 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

ARB-199 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

ARB-596 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

CCC-0346 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

CCC-0975 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

CYT-003QbG10 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Small Molecules to Inhibit HBsAg for Hepatitis B 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

DVR-23 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Small Molecules for Hepatitis B Infection 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Small Molecules to Agonize Sting Receptor for Hepatitis B 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Small Molecules to Inhibit Ribonuclease H for Hepatitis B 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Arbutus Biopharma Corporation - Pipeline Analysis 35

Arbutus Biopharma Corporation - Pipeline Products by Target 35

Arbutus Biopharma Corporation - Pipeline Products by Route of Administration 36

Arbutus Biopharma Corporation - Pipeline Products by Molecule Type 37

Arbutus Biopharma Corporation - Pipeline Products by Mechanism of Action 38

Arbutus Biopharma Corporation - Recent Pipeline Updates 39

Arbutus Biopharma Corporation - Dormant Projects 44

Arbutus Biopharma Corporation - Discontinued Pipeline Products 45

Discontinued Pipeline Product Profiles 45

INX-3280 45

NVP-018 45

RNAi Oligonucleotide to Inhibit CSN5 for Hepatocellular Carcinoma 45

RNAi Oligonucleotide to Inhibit WEE1 for Hepatocellular Carcinoma 45

Small Molecules for Dengue 46

TKM-100802 46

TKM-130803 46

TKM-ALDH2 46

TKM-GSD 46

TKM-HTG 46

TKM-Marburg 46

TKM-PLK1 46

TKMApoC-3 46

Arbutus Biopharma Corporation - Locations And Subsidiaries 47

Head Office 47

Other Locations & Subsidiaries 47

Appendix 48

Methodology 48

Coverage 48

Secondary Research 48

Primary Research 48

Expert Panel Validation 48

Contact Us 48

Disclaimer 49

List of Tables

List of Tables

Arbutus Biopharma Corporation, Key Information 6

Arbutus Biopharma Corporation, Key Facts 6

Arbutus Biopharma Corporation - Pipeline by Indication, 2016 8

Arbutus ...

List of Tables

Arbutus Biopharma Corporation, Key Information 6

Arbutus Biopharma Corporation, Key Facts 6

Arbutus Biopharma Corporation - Pipeline by Indication, 2016 8

Arbutus Biopharma Corporation - Pipeline by Stage of Development, 2016 9

Arbutus Biopharma Corporation - Monotherapy Products in Pipeline, 2016 10

Arbutus Biopharma Corporation - Partnered Products in Pipeline, 2016 11

Arbutus Biopharma Corporation - Partnered Products/ Combination Treatment Modalities, 2016 12

Arbutus Biopharma Corporation - Out-Licensed Products in Pipeline, 2016 13

Arbutus Biopharma Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2016 14

Arbutus Biopharma Corporation - Phase II, 2016 15

Arbutus Biopharma Corporation - Preclinical, 2016 16

Arbutus Biopharma Corporation - Discovery, 2016 17

Arbutus Biopharma Corporation - Pipeline by Target, 2016 35

Arbutus Biopharma Corporation - Pipeline by Route of Administration, 2016 36

Arbutus Biopharma Corporation - Pipeline by Molecule Type, 2016 37

Arbutus Biopharma Corporation - Pipeline Products by Mechanism of Action, 2016 38

Arbutus Biopharma Corporation - Recent Pipeline Updates, 2016 39

Arbutus Biopharma Corporation - Dormant Developmental Projects,2016 44

Arbutus Biopharma Corporation - Discontinued Pipeline Products, 2016 45

Arbutus Biopharma Corporation, Subsidiaries 47

List of Figures

List of Figures

Arbutus Biopharma Corporation - Pipeline by Stage of Development, 2016 9

Arbutus Biopharma Corporation - Monotherapy Products in Pipeline, 2016 10

Arbutus ...

List of Figures

Arbutus Biopharma Corporation - Pipeline by Stage of Development, 2016 9

Arbutus Biopharma Corporation - Monotherapy Products in Pipeline, 2016 10

Arbutus Biopharma Corporation - Partnered Products in Pipeline, 2016 11

Arbutus Biopharma Corporation - Out-Licensed Products in Pipeline, 2016 13

Arbutus Biopharma Corporation - Pipeline by Target, 2016 35

Arbutus Biopharma Corporation - Pipeline by Route of Administration, 2016 36

Arbutus Biopharma Corporation - Pipeline by Molecule Type, 2016 37

Arbutus Biopharma Corporation - Pipeline Products by Mechanism of Action, 2016 38

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports